Atara Biotherapeutics (FRA:AT2) Additional Paid-In Capital : €1,750.43 Mil(As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Additional Paid-In Capital?

Atara Biotherapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€1,741.34 Mil) to Dec. 2023 (€1,714.89 Mil) but then increased from Dec. 2023 (€1,714.89 Mil) to Mar. 2024 (€1,750.43 Mil).

Atara Biotherapeutics's annual additional paid-in capital increased from Dec. 2021 (€1,544.06 Mil) to Dec. 2022 (€1,719.71 Mil) but then declined from Dec. 2022 (€1,719.71 Mil) to Dec. 2023 (€1,714.89 Mil).

Atara Biotherapeutics Additional Paid-In Capital Historical Data

The historical data trend for Atara Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Additional Paid-In Capital Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

997.66

1,304.20

1,544.06

1,719.71

1,714.89

Atara Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,712.94	1,705.04	1,741.34	1,714.89	1,750.43

Atara Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Atara Biotherapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics (FRA:AT2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (FRA:AT2) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ATRA:USA AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (FRA:AT2) Headlines

No Headlines